指尖采血干血斑法助力阿达木单抗及抗药抗体治疗药物监测
该横断面研究纳入161例风湿性炎症疾病患者,同步采集指尖干血斑(DBS)与静脉血清,用ELISA和抗原结合试验分别检测阿达木单抗及抗阿达木单抗抗体(ADA)浓度。DBS法与血清结果相关性良好(相关系数>0.87),并建立约1.2的校正因子,提示指尖DBS可简化阿达木单抗TDM。
要点
- 指尖DBS检测阿达木单抗及ADA与血清结果相关性良好(相关系数>0.87)。
- DBS中抗体浓度系统性低于血清,需用约1.2校正因子换算。
- 指尖自采样DBS有望简化阿达木单抗的治疗药物监测流程。
核心结论
- 指尖采血DBS洗脱液可满意估算阿达木单抗及ADA血清浓度,为简化TDM提供机会。
研究设计与样本
- 横断面研究,纳入161例连续的风湿性炎症疾病患者,同步采集指尖DBS与静脉血清。
- 阿达木单抗用ELISA检测,ADA用抗原结合试验(ABT)检测。
- 研究比较五种将DBS洗脱液结果转换为可对比血清浓度的方法,包括标记蛋白法和体积法。
主要发现
- DBS法与血清法检测阿达木单抗和ADA浓度相关性良好,相关系数>0.87。
- DBS中阿达木单抗、ADA及总免疫球蛋白G浓度系统性低于血清,而白蛋白无此现象。
- 加标实验显示DBS中所有测试蛋白均定量回收,提示指尖采血与静脉采血蛋白组成略有差异。
- 建立约1.2的校正因子用于将指尖DBS值与血清值关联。
关键数值与推荐
- DBS与血清检测结果相关系数>0.87。
- 校正因子约为1.2。
临床怎么用
- 临床可考虑用指尖DBS自采样替代静脉采血进行阿达木单抗及ADA的TDM。
- 解读DBS结果时需应用约1.2的校正因子换算为血清等效浓度。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases. METHODS: In this cross-sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach. RESULTS: Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2). CONCLUSIONS: We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab.
引用
- Kneepkens EL, Pouw MF, Wolbink GJ, et al. Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. Br J Clin Pharmacol. 2017. PMID: 28791718. doi:10.1111/bcp.13371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。